SEC Form 4 · accession 0001213900-26-101883
ADIAL PHARMACEUTICALS, INC. · ADIL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendy B. Young
Director
Period of report
Sep 17, 2026
Accepted (ET)
Sep 21, 2026 · 7:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001513525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $2.98 | Sep 17, 2026 | A | 25,666 | A | — | Jun 12, 2036 | Common Stock | 25,666 | 25,666 | D |
Explanation of responses
- F1On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 ("Stockholder Approval Date").
- F22,138 shares subject to the stock option vested on the Stockholder Approval Date and the remaining 23,528 shares subject to the stock option shall vest in substantially equal installments over a 33-month period, beginning on October 12, 2026.